SAN DIEGO, May 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics Inc. ("Bionano" or the "Company") (NASDAQ:BNGO) today announced that it has completed a private placement of senior secured convertible debentures due May 24, 2026. The Company received gross proceeds of $18.0 million in connection with the placement, which will allow the Company to completely retire the convertible debt financing previously entered into first in October 2023, and then subsequently amended in February 2024. This new financing rein ...

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced significant upgrades to its suite of computational tools for comprehensive cancer analysis. These advancements to the company's VIA™ software solution enhance the detection and interpretation of aneusomies, and improve the analysis, visualization, interpretation, and reporting of data types including optical genome mapping (OGM), next generation sequencing, and microarray, for comprehensive assessment of hematol ...

Start Time: 16:30 January 1, 0000 4:27 PM ET Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2024 Earnings Conference Call May 08, 2024, 16:30 PM ET Company Participants Erik Holmlin - President and CEO Gülsen Kama - CFO David Holmes - IR Conference Call Participants Sung Ji Nam - Scotiabank Operator Good day, and welcome to the Bionano First Quarter 2024 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to David Holmes from Investor Relations. P ...

Table of Contents ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-38613 _________________________________________________________ Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq Stock Market, LLC Large accelerated filer ☐ Accelerated filer ...

• Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023 • Conference call today, May 8 , 2024, at 4:30 PM ET th Recent Highlights • Installed base of OGM systems totaled 347 at the end of the first quarter of 2024, which represents a 34% increase over the 259 installed systems reported at the end of the first quarter of 2023. ◦ In a study on hereditary breast and ovarian cancer syndrome, researchers used OGM to detect SVs in tumors that may be linked to mutated genes and altered si ...

Q1 2024 revenue was $8.8 million, which represents an 18% increase over Q1 2023Total installed base of 347 optical genome mapping (OGM) systems as of Q1 2024, which represents a 34% increase over Q1 2023Sold 8,249 nanochannel array flowcells in Q1 2024, which represents a 58% increase over the number of flowcells sold in Q1 2023Efforts to reduce cash burn and operating expense continued with the March 2024 announcement of expanded cost savings initiatives; since the initial cost savings initiative announced ...

Many investors abandon highly promising shares with little chance of failing. The phenomenon has been exacerbated by overdone fears about elevated interest rates. Short sellers often believe that elevated rates will crush indebted, money-losing firms, regardless of their potential. These short sellers put huge downward pressure on small companies that are still in the red and have some debt. As their stock prices sink, many other investors also avoid buying their shares. As a result, the stocks keep continu ...

Bionano, a global leader in the transformation of the cytogenetic workflow with optical genome mapping (OGM), has entered into a strategic partnership with Hangzhou Diagens Biotechnology Co., Ltd. (Diagens), the pioneering leader in artificial intelligence (AI) chromosome karyotype analysis technology. Their joint endeavor aims to commercialize the first ever cytogenetic workflow that integrates OGM plus AI chromosome karyotype analysisDiagens will become an original equipment manufacturing (OEM) partner of ...

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,733,626 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 8,733,626 shares of its common stock at an offering price of $1.145 per share of common stock (or per common stock equivalent in lieu thereof) and accompanying warrant, in a registered direct ...

Nine scientific posters will illustrate the application of optical genome mapping (OGM) in cancer research areas including hematological malignancies, solid tumors, and applications in cell and gene therapy, cell manufacturing and bioprocessing quality controlBionano is introducing its new Stratys™ system for high throughput OGM to the cancer research communityBionano will preview VIA™ 7.1 software, an upcoming advancement to the Company's software for visualization, interpretation and reporting of OGM, nex ...